Antiplatelet agents are the mainstay treatment in the prevention and management of
atherothrombotic complications. However, a substantial interpatient variability in response to …

The management of patients with coronary artery stents during the perioperative period is
one of the most important patient safety issues clinicians confront. Perioperative stent …

Dual antiplatelet therapy (DAPT) has remained the cornerstone for management of acute
coronary syndrome (ACS) over the years. Clopidogrel has been the quintessential P2Y12 …

The subspecialty of interventional cardiology has made significant progress in the
management of coronary artery disease over the past three decades with the development …

The P2Y1 and P2Y12 purinergic receptors are responsible for mediating adenosine
diphosphate (ADP) dependent platelet aggregation. Evidence from P2Y1 knockout studies …

Acute coronary syndrome is the number one killer in the industrialized world and, as such,
continues to be one of the most well-studied disease states in all of medicine …

The platelet, once thought to be solely involved in clot formation, is now known to be a key
mediator in various other processes such as inflammation, thrombosis, and atherosclerosis …

Platelets from patients affected by diabetes mellitus and metabolic syndrome show an
impaired sensitivity to physiological antiaggregating agents and an enhanced activation …

Patients with established coronary heart disease (CHD) have a high risk of subsequent
cardiovascular events, including myocardial infarction (MI), stroke, and death from …

Benzofuran-substituted urea analogs have been identified as novel P2Y1 receptor
antagonists. Structure–activity relationship studies around the urea and the benzofuran …